Sugi Predict

Sugi Predict / Compounds / SCHEMBL2032500

SCHEMBL2032500

SCHEMBL2032500

Fc1ccccc1-n1cnc2cnc3ccc(Cl)cc3c21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR1 Q9BXC0 2/20 0.45
▸ FGFR1 P11362 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ GABRA2 P47869 1/20 0.39
▸ GABRA6 Q16445 1/20 0.39
▸ MAP3K8 P41279 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ STAT3 P40763 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2038322 0.88 HCAR1 (0.46) HCAR1FGFR1KDM4EGABRA1GABRG2
SCHEMBL2033054 0.86 HCAR1 (0.47) HCAR1KDM4EMAP3K8RAB9ALMNA
SCHEMBL2037744 0.86 HCAR1 (0.44) HCAR1FGFR1KDM4EGABRA1GABRG2
SCHEMBL2030667 0.86 MAP3K8 (0.39) HCAR1FGFR1KDM4EGABRA1GABRG2
SCHEMBL2036673 0.86 HCAR1 (0.44) HCAR1FGFR1KDM4EGABRA1GABRG2
SCHEMBL2252364 0.84 HCAR1 (0.45) HCAR1KDM4EGABRA1GABRG2GABRB3
SCHEMBL2035100 0.84 HCAR1 (0.47) HCAR1FGFR1GABRA1GABRG2GABRB3
SCHEMBL2030991 0.83 CLK1 (0.47) HCAR1MAP3K8PIK3CA
SCHEMBL2031506 0.83 PDPK1 (0.38) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2037728 0.83 HCAR1 (0.47) HCAR1FGFR1KDM4ERAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998972-B2 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2011-08-16 — — US claimed
JP-4707389-B2 — — 2011-06-22 — — JP claimed
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2005-11-03 — — US claimed
EP-1509521-A2 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-02 — — EP claimed
WO-2003097641-A2 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-11-27 — — WO claimed
EP-1509521-B1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2008-08-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases ABL1, PRKCA, PRKCQ HCAR1 4108/4885FGFR1 3042/4885KDM4E 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.